Implanted a programmable micropump smart device that delivers precise small doses of medications into the eyes of patients with diabetic macular edema, in the first-in-man clinical trial
USC Roski Eye Institute Patient Becomes First Blind Patient to have Two artificial retinal prostheses, Argus I and newest generation of Argus II –one in each eye
Dr. Mark Humayun honored by President Barack Obama with the National Medal of Technology and Innovation
Two FDA-approvals this year- corneal cross-linking (CXL), an innovative procedure that provides effective treatment for keratoconus, and the XEN Glaucoma Treatment System, which reduces intraocular pressure with a tiny flexible stent that is implanted using an injector applicator
Visionary Care, Research & Education
Are you in search of eye care that will not only address your pressing health concerns, but set a path for you to reach a happier and healthier everyday life? The USC Roski Eye Institute has been providing cutting-edge eye care for over 40 years and treats hundreds of patients on a daily basis. By providing ophthalmology treatments that are tailored to each patient’s unique needs, you can rest assured that you will receive both the time and care that you deserve for your condition.
Because of our commitment to high quality eye care, the USC Roski Eye Institute has consistently ranked in the top 10 for ophthalmology programs in publications such as U.S. News and World Report and Ophthalmology Times. We are also one of the top federally funded institutes in the world. This funding means that we have an unparalleled ability to delve into groundbreaking research across the field of ophthalmology.
With locations in Los Angeles, Beverly Hills, Arcadia, and Pasadena, we are able to provide timely treatments for patients across southern California. Whether you are looking for an assessment of minor eyesight problems or help with life-changing ophthalmic conditions, our specialized eye care team has the insight and expertise that you need. To speak with our ophthalmology team, learn more about our treatment options, and schedule an appointment, call 323-442-6335 or fill out our online contact form.
An Inside Look at USC Roski Eye Institute
In 1974, USC Keck School of Medicine established the USC Department of Ophthalmology, which grew into the USC Roski Eye Institute and became an essential regional, national and global leader in the field. The USC Roski Eye Institute has more than 135 faculty covering all subspecialties of ophthalmology. In addition to the Top 10 ranking by U.S. News & World Report for 21 years, the USC Department of Ophthalmology is No. 2 in research funding from the National Eye Institute. Over the past four decades, USC Roski Eye Institute faculty members have received international acclaim for their contributions to vision research, including the development of optical coherence tomography (OCT) and OCT angiography, a non-invasive imaging technique used to diagnose glaucoma, diabetic eye disease, macular degeneration and other retinal and optic nerve disorders, the Baerveldt glaucoma implant, the world’s most widely used glaucoma implant and the XEN implant – the most effective minimally invasive glaucoma surgery. USC Roski Eye Institute physician scientists developed the only commercially available retinal prosthesis, Argus II Retinal Prosthesis System, to restore vision to those blind from retinitis pigmentosa and a long-term ocular drug delivery pump for the treatment of diabetic eye disease and macular degeneration. Currently, the USC Roski Eye Institute is one of the few centers enrolling patients for stem cell-based treatments for macular degeneration. The USC Roski Eye Institute also is one of the leading eye centers in the world studying the burden of vision loss and its impact on quality of life among vulnerable populations such as children and minorities.
Our most recent major breakthroughs include the following:
- Debuting California’s first certified ophthalmic education program, one of only 13 in the nation
- Leading NEI eye disease research among multi-ethnic populations
- Inventing the FDA-approved XEN stent, the most widely used glaucoma implant in the world
- Changing health care policy in the United States – our world-renowned population-based health studies have led to new treatment and prevention initiatives
- Leading researchers of eye disease prevention and treatment as part of the Human Connectome brain mapping research
- Pioneering use of ultra-high speed Fourier domain optical coherence tomography (OCT) – revolutionized how ophthalmologists diagnose diseases of the eye
- Inventing the world’s first FDA-approved artificial retina, Argus II – this device has brought an unprecedented degree of sight back to those blinded by retinitis pigmentosa
- Developing a new stem cell therapy for age-related macular degeneration
- Discovering the mutation in retinal cells that causes retinoblastomas – the most common type of eye cancer in children
- Pioneered use of OCT Angiography for diagnosis and management of retinal vascular diseases. USC Roski Eye Institute, was one of two research sites to conduct preclinical pilot studies using prototype OCT Angiography devices which was FDA approved for clinical use
- USC Roski Eye Institute Patient Becomes First Blind Patient to have Two artificial retinal prostheses, Argus I and newest generation of Argus II –one in each eye
These breakthroughs offer hope to those suffering from vision loss and allow patients access to cutting-edge care.
Next, read about our residency and fellowship.